Abingen Ltd Report issue

For profit Phase 1
Founded: Nanjing China (2014)
Status: Acquired by Beike Biotech (2015)

Organization Overview

First Clinical Trial
2016
NCT02662348
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Abingen Ltd, Nanjing

Active Ingredients

Drugs in Phase 1 Trials (2)

aldesleukin (Proleukin) (1 trial)

her2bi-armed activated t cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Digestive System Neoplasms (Phase 1)

Gallbladder Neoplasms (Phase 1)

Gastrointestinal Neoplasms (Phase 1)

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 2